Regeneron Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Regeneron Pharmaceuticals has a total shareholder equity of $29.3B and total debt of $2.0B, which brings its debt-to-equity ratio to 6.8%. Its total assets and total liabilities are $37.4B and $8.1B respectively. Regeneron Pharmaceuticals's EBIT is $4.1B making its interest coverage ratio -6.7. It has cash and short-term investments of $9.8B.
Key information
6.8%
Debt to equity ratio
US$1.98b
Debt
| Interest coverage ratio | -6.7x |
| Cash | US$9.80b |
| Equity | US$29.33b |
| Total liabilities | US$8.12b |
| Total assets | US$37.44b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: RGO's short term assets ($19.3B) exceed its short term liabilities ($3.7B).
Long Term Liabilities: RGO's short term assets ($19.3B) exceed its long term liabilities ($4.5B).
Debt to Equity History and Analysis
Debt Level: RGO has more cash than its total debt.
Reducing Debt: RGO's debt to equity ratio has increased from 0% to 6.8% over the past 5 years.
Debt Coverage: RGO's debt is well covered by operating cash flow (214.1%).
Interest Coverage: RGO earns more interest than it pays, so coverage of interest payments is not a concern.